<html>
<head>
    <script language="JavaScript" src="http://code.jquery.com/jquery-1.4.4.js"></script>
    <script language="JavaScript" src="../js/pie.js"></script>
    <script language="JavaScript" src="../js/browser_adjust.js"></script>
    <script language="JavaScript" src="../js/search.js"></script>


    <script type="text/JavaScript">
    <!--

    var array = [[5.7145045637, "../topics/{stock,_price,_share}.html", "{stock,_price,_share}"], [5.6565625339, "../topics/{product,_liability,_claim}.html", "{product,_liability,_claim}"], [4.88854481, "../topics/{product,_candidate,_development}.html", "{product,_candidate,_development}"], [3.6884888105, "../topics/{customer,_product,_revenue}.html", "{customer,_product,_revenue}"], [3.6480991954, "../topics/{debt,_indebtedness,_cash}.html", "{debt,_indebtedness,_cash}"], [1.9365334152, "../topics/{product,_market,_service}.html", "{product,_market,_service}"], [1.7306890767, "../topics/{cost,_regulation,_environmental}.html", "{cost,_regulation,_environmental}"], [1.720677097, "../topics/{personnel,_key,_retain}.html", "{personnel,_key,_retain}"], [1.7191215448, "../topics/{provision,_law,_control}.html", "{provision,_law,_control}"], [1.7133110669, "../topics/{property,_intellectual,_protect}.html", "{property,_intellectual,_protect}"]];
    var elements = generate_pie_elements(array);
    var piec = null;
    function init() {
        browser_adjust();
        
        // create pie chart
        piec = new PieChart(elements);
        piec.initialize();

    }

    function highlight(i) {
        piec.highlight(i);
    }
    
    function unhighlight() {
        piec.unhighlight();
    }
    //-->
    </script>

    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    
    <title>727510--2/29/2008--ENZON_PHARMACEUTICALS_INC</title>

    <link href="../styling.css" rel="stylesheet" type="text/css">
</head>

<body onLoad="init()">
<div id="navigation">
<hr noshade>
<table><tr>
    <td class="navtext">Browse&nbsp;&#x25B8;</td> 
    <td class="linked"><a>Topics</a>
      <ul> 
        <li><a href="../browse/topic-list.html">List of Terms</a></li> 
        <li><a href="../browse/topic-graph.html">Term Distributions</a></li> 
        <li><a href="../browse/topic-presence.html">Relative Presence</a></li>
      </ul> 
    </td> 
    <td class="linked"><a>Documents</a>
      <ul>
        <li><a href="../browse/doc-graph.html">Topic Distributions</a></li>
      </ul> 
    </td>
    <td class="linked"><a>Terms</a>
      <ul> 
        <li><a href="../browse/term-list.html">List by Frequency</a></li> 
        <li><a href="../browse/term-graph.html">Topic Distributions</a></li> 
       </ul> 
    </td>
    <td class="linked"><a>About</a>
      <ul>
        <li><a href="http://www.cs.princeton.edu/~blei/lda-c/">LDA</a></li>
      </ul> 
    </td>
    
    </td>
    <td></td>
    <td class="searchbar"> Search&nbsp;&#x25B8;</td>
    <td class="searchbar"><input type="text" name="search" size="20" onkeypress="handleKeyPress(event)"><span onclick="doSearch()"></span>
    </td>
</tr></table>
</div>

    <div id="top"></div>

    <h1 id="header">
        <table><tr>
            <td id="title">727510--2/29/2008--ENZON_PHARMACEUTICALS_INC</td>
        </tr></table>

        <hr noshade>
    </h1>

    <div id="main">
        <table><tr>
            <td width="210px">
                <table class="dark">
                <tr><td><canvas id="canvas" width="200" height="200"></canvas></td></tr>
                <tr class="title">
                    <td>related topics</td>
                </tr>
                <tr class="list"><td id="{stock,_price,_share}" onmouseover="highlight(0)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{stock,_price,_share}.html'">{stock, price, share}</td></tr>
<tr class="list"><td id="{product,_liability,_claim}" onmouseover="highlight(1)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_liability,_claim}.html'">{product, liability, claim}</td></tr>
<tr class="list"><td id="{product,_candidate,_development}" onmouseover="highlight(2)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_candidate,_development}.html'">{product, candidate, development}</td></tr>
<tr class="list"><td id="{customer,_product,_revenue}" onmouseover="highlight(3)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{customer,_product,_revenue}.html'">{customer, product, revenue}</td></tr>
<tr class="list"><td id="{debt,_indebtedness,_cash}" onmouseover="highlight(4)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{debt,_indebtedness,_cash}.html'">{debt, indebtedness, cash}</td></tr>
<tr class="list"><td id="{product,_market,_service}" onmouseover="highlight(5)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_market,_service}.html'">{product, market, service}</td></tr>
<tr class="list"><td id="{cost,_regulation,_environmental}" onmouseover="highlight(6)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{cost,_regulation,_environmental}.html'">{cost, regulation, environmental}</td></tr>
<tr class="list"><td id="{personnel,_key,_retain}" onmouseover="highlight(7)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{personnel,_key,_retain}.html'">{personnel, key, retain}</td></tr>
<tr class="list"><td id="{provision,_law,_control}" onmouseover="highlight(8)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{provision,_law,_control}.html'">{provision, law, control}</td></tr>
<tr class="list"><td id="{property,_intellectual,_protect}" onmouseover="highlight(9)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{property,_intellectual,_protect}.html'">{property, intellectual, protect}</td></tr>

                </table>
            </td>

            <td>
                <table class="light">
                <tr class="doc"><td>
                    Our financial results are heavily dependent on the continued sales of our marketed products and the products on which we receive royalties; if revenues from these products fail to increase or materially decline, our results of operations, financial position and prospects could be materially harmed.
Sales of PEG-INTRON and Abelcet have been adversely affected by competitive products introduced into their respective markets and we have experienced in the past and may continue to experience in the future a decline in sales of Abelcet, which if not reversed, will adversely affect our results of operations, financial condition and prospects.
We will need to obtain additional financing to meet our future capital needs and our significant debt level may adversely affect our ability to do so. Failure to do so could materially and adversely affect our business, financial condition and operations.
We depend on our collaborative partners; if we lose our collaborative partners or they do not apply adequate resources to our collaborations, our product development and financial performance may suffer.
We purchase some of the compounds utilized in our products from a single source or a limited group of suppliers, and the partial or complete loss of one of these suppliers could cause production delays and a substantial loss of revenues.
Our product candidates must undergo extensive clinical testing, the results of which are uncertain and could substantially delay or prevent us from obtaining regulatory approval.
We depend on patents and proprietary rights, which may offer only limited protection against potential infringement and the development by our competitors of competitive products. The U.S. and foreign patents upon which our original PEG technology was based have expired.
We or our suppliers could experience delays or difficulties in manufacturing, including problems complying with the FDA s regulations for manufacturing our products. These problems could materially harm our business.
Our arrangements with third-party manufacturers involve significant financial commitments and costs that may be incurred if we terminate or delay manufacturing.
We may be subject to a variety of types of product liability or other claims based on allegations that the use of our products has resulted in adverse effects, whether by participants in our clinical trials or by patients using our products, and our insurance may not cover all product liability or other claims.
We depend on key personnel and may not be able to retain these employees or recruit additional qualified personnel, which would harm our business.
Risks Related to Our Industry
We face rapid technological change and intense competition, which could harm our business and results of operations.
The regulatory approval process is highly uncertain and we may not successfully secure approval for new products. Failure to obtain, or delays in obtaining, regulatory approvals could materially harm our business.
Even if we obtain regulatory approval for our products, they may not be accepted in the marketplace.
Our operations are subject to extensive environmental laws and regulations.
Because of the uncertainty of pharmaceutical pricing, reimbursement and healthcare reform measures, we may be unable to sell our products profitably in the U.S.
The law or FDA policy could change and expose us to competition from generic or follow-on versions of our products, which could adversely impact our business.
Risks Related to Our Common Stock and our Convertible Notes
The price of our common stock has been, and may continue to be, volatile, which also may significantly affect the trading price of our convertible notes.
Events with respect to our share capital could cause the shares of our common stock outstanding to increase.
Anti-takeover provisions in our charter documents and under Delaware law may make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.
The issuance of preferred stock may adversely affect rights of common stockholders.
We may be unable to redeem our 2013 convertible notes upon a fundamental change.
The market for unrated debt is subject to disruptions that could have an adverse effect on the market price of the 2013 convertible notes, or a market for our notes may fail to develop or be sustained.
We may not have sufficient funds available to pay amounts due under our 2013 convertible notes.
<p><a href="http://www.sec.gov/Archives/edgar/data/727510/0000950123-08-002345.txt">Full 10-K form&nbsp;&#x25B8;</a></p>
                </td></tr>
                </table>
            </td>

            <td width="25%">
                <table class="dark">
                <tr class="title">
                    <td>related documents</td>
                </tr>
                <tr class="list"><td onclick="window.location.href='../docs/930553--3-16-2007--ISTA_PHARMACEUTICALS_INC.html'">930553--3/16/2007--ISTA_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/893970--11-15-2007--INTERPHARM_HOLDINGS_INC.html'">893970--11/15/2007--INTERPHARM_HOLDINGS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1059784--10-16-2006--GENEREX_BIOTECHNOLOGY_CORP.html'">1059784--10/16/2006--GENEREX_BIOTECHNOLOGY_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1059784--10-15-2007--GENEREX_BIOTECHNOLOGY_CORP.html'">1059784--10/15/2007--GENEREX_BIOTECHNOLOGY_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1059784--10-10-2008--GENEREX_BIOTECHNOLOGY_CORP.html'">1059784--10/10/2008--GENEREX_BIOTECHNOLOGY_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/821995--3-13-2006--COLUMBIA_LABORATORIES_INC.html'">821995--3/13/2006--COLUMBIA_LABORATORIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/893970--9-28-2006--INTERPHARM_HOLDINGS_INC.html'">893970--9/28/2006--INTERPHARM_HOLDINGS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/821995--3-16-2007--COLUMBIA_LABORATORIES_INC.html'">821995--3/16/2007--COLUMBIA_LABORATORIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/3116--3-30-2009--AKORN_INC.html'">3116--3/30/2009--AKORN_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/749647--3-20-2006--CELSION_CORP.html'">749647--3/20/2006--CELSION_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/749647--3-28-2008--Celsion_CORP.html'">749647--3/28/2008--Celsion_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/3116--3-16-2010--AKORN_INC.html'">3116--3/16/2010--AKORN_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/930553--3-6-2006--ISTA_PHARMACEUTICALS_INC.html'">930553--3/6/2006--ISTA_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1057377--4-14-2008--SAMARITAN_PHARMACEUTICALS_INC.html'">1057377--4/14/2008--SAMARITAN_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1003464--3-16-2007--ENDOCARE_INC.html'">1003464--3/16/2007--ENDOCARE_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1450552--12-29-2010--Dafoe_Corp..html'">1450552--12/29/2010--Dafoe_Corp.</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/879682--3-28-2008--PLC_SYSTEMS_INC.html'">879682--3/28/2008--PLC_SYSTEMS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1159036--3-13-2009--HALOZYME_THERAPEUTICS_INC.html'">1159036--3/13/2009--HALOZYME_THERAPEUTICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/749647--3-27-2009--Celsion_CORP.html'">749647--3/27/2009--Celsion_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1114872--3-19-2008--MILLENNIUM_CELL_INC.html'">1114872--3/19/2008--MILLENNIUM_CELL_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/884847--3-21-2006--MATRITECH_INC-DE-.html'">884847--3/21/2006--MATRITECH_INC/DE/</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1030839--2-5-2009--Synovics_Pharmaceuticals.html'">1030839--2/5/2009--Synovics_Pharmaceuticals</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/749647--3-17-2010--Celsion_CORP.html'">749647--3/17/2010--Celsion_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/826253--6-13-2008--AURA_SYSTEMS_INC.html'">826253--6/13/2008--AURA_SYSTEMS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/725460--3-31-2006--LANGER_INC.html'">725460--3/31/2006--LANGER_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/883975--3-11-2010--STEMCELLS_INC.html'">883975--3/11/2010--STEMCELLS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/719722--2-10-2009--CARDIODYNAMICS_INTERNATIONAL_CORP.html'">719722--2/10/2009--CARDIODYNAMICS_INTERNATIONAL_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1159036--3-9-2007--HALOZYME_THERAPEUTICS_INC.html'">1159036--3/9/2007--HALOZYME_THERAPEUTICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/883975--3-16-2009--STEMCELLS_INC.html'">883975--3/16/2009--STEMCELLS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/886235--3-17-2008--ASPECT_MEDICAL_SYSTEMS_INC.html'">886235--3/17/2008--ASPECT_MEDICAL_SYSTEMS_INC</td></tr>

                </table>
            </td>
        </tr></table>
    </div>

    <div id="footer">
        <br>
        <hr noshade>
    </div>
</body>
</html>
